The crystal structure of the catalytic domain of human urokinase-type plasminogen activator

Structure

Volumn 3, Issue 7, 1995, Pages 681-691

  Spraggon, Glen ^a,c,e   Phillips, Christopher ^a,c,e   Nowak, Ursula K ^b,c,e   Ponting, Christopher P ^b,c,e   Saunders, Derek ^c,d,e   Dobson, Christopher M ^b,c,e   Stuart, David I ^b,c,e   Jones, E Yvonne ^a,c,e  

^a Glen Spraggon ^*

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d GRÜNENTHAL GMBH   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

fibrinolysis; inhibitor protein interaction; serine protease; variable regions; X ray crystallography

Indexed keywords

CHYMOTRYPSIN; RECOMBINANT PROTEIN; THROMBIN; UROKINASE;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; GLYCOSYLATION; HUMAN; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; SEQUENCE HOMOLOGY; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; BINDING SITES; CHYMOTRYPSIN; COMPARATIVE STUDY; CRYSTALLOGRAPHY, X-RAY; GLYCOSYLATION; HUMAN; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SUPPORT, NON-U.S. GOV'T; THROMBIN; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029645121     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(01)00203-9     Document Type: Article

References (57)

1. The plasminogen activator/plasmin system
2. Fibrinolytic properties of single chain urokinase-type plasminogen activator (pro-urokinase)
3. The primary structure of high molecular mass urokinase from human urine The complete amino acid sequence of the A-chain
4. The complete amino acid sequence of low molecular mass urokinase from human urine
5. The receptor-binding sequence of urokinase
6. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
7. Plasminogen activators tissue degradation and cancer
8. Urokinase-type plasminogen activator and malignancy
9. Physiological consequences of loss of plasminogen activator gene function in mice
10. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and 2
11. Crystalline human urokinase: some properties
12. Dynamics of the multidomain fibrinolytic protein urokinase from two-dimensional NMR
13. Domain structure and interactions of recombinant urokinase-type plasminogen activator
14. NMR studies of the dynamics of the multidomain protein urokinase-type plasminogen activator
15. Unfolding studies of the protease domain of urokinase-type plasminogen activator: the existence of partly folded states and stable sub-domains
16. 15N relaxation studies of the amino-terminal fragment of urokinase-type plasminogen activator
17. Solution structure of the kringle domain from urokinase-type plasminogen activator
18. Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator
19. The refined 1.9 å crystal structure of human α- thrombin: interaction with D–Phe–Pro–Arg chloromethylketone and significance of the Tyr–Pro–Pro–Trp insertion segment
20. Structure of human Des(1–45) Factor Xa at 2.2 å resolution
21. Structure of human Factor D. A complement system protein at 2.0 å resolution
22. Crystallographic R-factor refinement by molecular dynamics
23. Structure of α-chymotrypsin refined at 1.68 å resolution
24. Stereochemical criteria for polypeptide and protein chain conformations. II. Allowed conformations for a pair of peptide units
25. Crystal structure of cat muscle pyruvate kinase at a resolution of 2.6 å
26. Comparative model-building of the mammalian serine proteases
27. Comparative modelling methods: applications to the family of mammalian serine proteases
28. A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor
29. Mutations affecting the activity of urokinase-type plasminogen activator
30. Activation of chymotrypsinogen-A: an hypothesis based upon the comparison of the crystal structures of chymotrypsinogen-A and α-chymotrypsin
31. Structural basis of the activation and action of trypsin
32. Subtilisin: a stereochemical mechanism involving transition-state stabilization
33. Converting tissue plasminogen activator to a zymogen: a regulatory triad of Asp–His–Ser
34. The refined 1.9 å X-ray crystal structure of D–Phe–Pro–Arg chloromethylketone-inhibited human α-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships
35. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons
36. The refined crystal structure of bovine β-trypsin at 1.8 å resolution. II. Crystallographic refinement, calcium binding site, benzamidine binding site and active site at pH 7
37. Three-dimensional structure of tosylelastase
38. Serine proteases: structure and mechanism of catalysis
39. Mechanism-based inactivators of trypsin-like proteinases. Selective inhibition of urokinase by functionalized cyclopeptides incorporating a bromomethyl-substituted m-aminobenzoic acid residue
40. Inhibition of urokinase by 4-substituted benzi[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor
41. Purification and characterization of recombinant urokinase from Escherichia coli
42. Sparse matrix sampling a screening method for crystallization of proteins
43. Automatic indexing of rotation diffraction patterns
44. DENZO: oscillation data reduction program
45. Solution of a Fab (26-10)/digoxin complex by generalized molecular replacement
46. Extension of molecular replacement a new search strategy based on Patterson correlation refinement
47. Accurate bond and angle parameters for X-ray protein structure refinement
48. Interactive computer graphics: FRODO
49. Improved methods for building models in electron density maps and the location of errors in these models
50. PROCHECK a program to check stereochemical quality of protein structures
51. MOLSCRIPT a program to produce both detailed and schematic plots of protein structures
52. RASTER3D version 20 a program for photorealistic molecular graphics
53. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain
54. Human plasma fibronectin as a substrate for human urokinase
55. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor
56. 2-terminal activation peptide as studied by affinity chromatography